Published in Int J Cancer on October 25, 2012
Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02
Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell (2013) 1.29
The utility of zebrafish to study the mechanisms by which ethanol affects social behavior and anxiety during early brain development. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.84
Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells. Mol Cancer (2015) 0.81
Independent evaluation of a FOXM1-based quantitative malignancy diagnostic system (qMIDS) on head and neck squamous cell carcinomas. Oncotarget (2016) 0.75
Integrin α11 is overexpressed by tumour stroma of head and neck squamous cell carcinoma and correlates positively with alpha smooth muscle actin expression. J Oral Pathol Med (2016) 0.75
Developmental role of acetylcholinesterase in impulse control in zebrafish. Front Behav Neurosci (2015) 0.75
FOXM1 allows human keratinocytes to bypass the oncogene-induced differentiation checkpoint in response to gain of MYC or loss of p53. Oncogene (2016) 0.75
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med (2012) 4.59
Nuchal translucency and gestational age. Prenat Diagn (2004) 2.77
Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2009) 2.58
Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum Mol Genet (2002) 2.41
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Drosophila liprin-alpha and the receptor phosphatase Dlar control synapse morphogenesis. Neuron (2002) 2.33
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2012) 2.33
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Attitudes to participation in a lung cancer screening trial: a qualitative study. Thorax (2011) 2.10
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 2.06
Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol (2005) 1.94
Highwire regulates presynaptic BMP signaling essential for synaptic growth. Neuron (2004) 1.91
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr (2009) 1.83
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res (2011) 1.54
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48
FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One (2009) 1.48
Prevalence of migraine on each day of the natural menstrual cycle. Neurology (2004) 1.46
Infraorbital orbitotomy: modification of the Weber-Ferguson approach. Br J Oral Maxillofac Surg (2009) 1.45
Benefits and harms of mammography screening. BMJ (2012) 1.42
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. Infect Immun (2006) 1.41
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res (2010) 1.27
Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol (2009) 1.24
MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One (2011) 1.23
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17
Lack of plakophilin 1 increases keratinocyte migration and reduces desmosome stability. J Cell Sci (2003) 1.16
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.16
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab Dispos (2010) 1.16
Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol (2002) 1.15
Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg (2007) 1.14
Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. Mol Cancer Ther (2008) 1.14
Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer (2010) 1.10
Retrotransposition of limited deletion type of intracisternal A-particle elements in the myeloid leukemia Clls of C3H/He mice. J Radiat Res (2004) 1.08
Effects of clinical characteristics on successful open access scheduling. Health Care Manag Sci (2007) 1.04
Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One (2011) 1.03
The role of histopathological characteristics in distinguishing amalgam-associated oral lichenoid reactions and oral lichen planus. J Oral Pathol Med (2006) 1.02
Interactions of lactoferricin-derived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett (2004) 1.01
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem (2009) 1.01
Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci (2009) 1.01
Human-like immune responses in CD46 transgenic mice. J Immunol (2005) 1.00
Application of methods for central statistical monitoring in clinical trials. Clin Trials (2013) 0.98
FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One (2012) 0.98
S100A14 inhibits proliferation of oral carcinoma derived cells through G1-arrest. Oral Oncol (2011) 0.97
Genomic profiles and CRTC1-MAML2 fusion distinguish different subtypes of mucoepidermoid carcinoma. Mod Pathol (2012) 0.96
S100A14 regulates the invasive potential of oral squamous cell carcinoma derived cell-lines in vitro by modulating expression of matrix metalloproteinases, MMP1 and MMP9. Eur J Cancer (2010) 0.95
Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. J Invest Dermatol (2002) 0.95
Efficacy of bovine bone mineral for alveolar augmentation: a human histologic study. Clin Oral Implants Res (2003) 0.95
Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol (2010) 0.95
Genital and cutaneous human papillomavirus (HPV) types in relation to conjunctival squamous cell neoplasia: a case-control study in Uganda. Infect Agent Cancer (2008) 0.94
Agrobacterium-mediated insertional mutagenesis (AIM) of the entomopathogenic fungus Beauveria bassiana. Curr Genet (2003) 0.94
Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle (2007) 0.93
DNA ploidy distribution in renal tumours induced in male rats by dietary ochratoxin A. Exp Toxicol Pathol (2007) 0.93
Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Cloning, expression, and purification of mouse heparanase. Protein Expr Purif (2002) 0.92
Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src. PLoS One (2010) 0.92
Keratin k15 as a biomarker of epidermal stem cells. Int J Mol Sci (2013) 0.92
Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2005) 0.92
Changes in the expression of stem cell markers in oral lichen planus and hyperkeratotic lesions. J Oral Sci (2007) 0.92
Odontogenic tumors, WHO 2005: where do we go from here? Head Neck Pathol (2014) 0.91
Cancer-associated cleavage of cytokeratin 8/18 heterotypic complexes exposes a neoepitope in human adenocarcinomas. J Biol Chem (2002) 0.91
Long-term safety from the raltegravir clinical development program. Curr HIV Res (2011) 0.91
Two mechanisms regulate keratin K15 expression in keratinocytes: role of PKC/AP-1 and FOXM1 mediated signalling. PLoS One (2012) 0.91
Association of a BMP9 haplotype with ossification of the posterior longitudinal ligament (OPLL) in a Chinese population. PLoS One (2012) 0.91
An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity. J Oral Pathol Med (2008) 0.91
Effect of rat Schwann cell secretion on proliferation and differentiation of human neural stem cells. Biomed Environ Sci (2003) 0.90
Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study. Toxins (Basel) (2010) 0.90
Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.90
Odontomas in the primary dentition: literature review and case report. J Dent Child (Chic) (2004) 0.89
The benefits and harms of mammographic screening for breast cancer: building the evidence base using service screening programmes. J Med Screen (2012) 0.89
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer (2007) 0.89
Thyroid hormones and gamma interferon specifically increase K15 keratin gene transcription. Mol Cell Biol (2004) 0.88
Species-specific fibroblasts required for triggering invasiveness of partially transformed oral keratinocytes. Am J Pathol (2006) 0.88
Severe cutaneous papillomavirus disease after haematopoietic stem-cell transplantation in patients with severe combined immunodeficiency. Br J Haematol (2004) 0.87
Long-term follow-up of mandibular condylar fractures in children. J Oral Maxillofac Surg (2011) 0.87
Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris. J Pathol (2012) 0.86
Desmoglein 3 acting as an upstream regulator of Rho GTPases, Rac-1/Cdc42 in the regulation of actin organisation and dynamics. Exp Cell Res (2012) 0.86
Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer. Cancer Med (2012) 0.86
Adducin expression in cutaneous and oral lesions: alpha- and beta-adducin transcripts down-regulate with keratinocyte differentiation in stratified epithelia. J Pathol (2003) 0.86
Implications of a positive sentinel node in oral squamous cell carcinoma. Head Neck (2012) 0.85
Khat (Catha edulis) induces reactive oxygen species and apoptosis in normal human oral keratinocytes and fibroblasts. Toxicol Sci (2008) 0.85
Expression of keratin K2e in cutaneous and oral lesions: association with keratinocyte activation, proliferation, and keratinization. Am J Pathol (2003) 0.85
MyD88-dependent signaling affects the development of meningococcal sepsis by nonlipooligosaccharide ligands. Infect Immun (2006) 0.85
Copy number and loss of heterozygosity detected by SNP array of formalin-fixed tissues using whole-genome amplification. PLoS One (2011) 0.85
Fusobacterium nucleatum enters normal human oral fibroblasts in vitro. J Periodontol (2009) 0.85
Variation in antimicrobial activity of lactoferricin-derived peptides explained by structure modelling. FEMS Microbiol Lett (2004) 0.85
Role of thyroidectomy in advanced laryngeal and pharyngolaryngeal carcinoma. Otolaryngol Head Neck Surg (2010) 0.84
Effect of low-intensity pulsed ultrasound on the expression of neurotrophin-3 and brain-derived neurotrophic factor in cultured Schwann cells. Microsurgery (2009) 0.84